



DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. [BI Divests Some Animal Health Assets in Sanofi Business Swap](#)

Boehringer Ingelheim (BI) has entered into an agreement with Ceva Santé Animale, an animal-health company headquartered in Libourne, France, under which Ceva will purchase certain portfolio assets of Merial, Sanofi's animal health business, as part of BI's previously announced business swap with Sanofi of the companies' animal health and consumer healthcare businesses. [Read More](#)

2. [BASF Suffers Explosion at Site in Ludwigshafen, Germany](#)

BASF experienced an explosion at its site in Ludwigshafen, Germany, on Monday October 17, 2016. The site is one of the largest chemical complexes globally. BASF has said it will gradually resume operations at two steam crackers affected in the explosion. [Read More](#)

3. [AstraZeneca Buys Second Amgen Biologics Manufacturing Facility](#)

AstraZeneca has purchased a second biologics manufacturing facility in Longmont, Colorado from Amgen that will be used to support AstraZeneca's existing operations at its nearby Boulder, Colorado site. AstraZeneca first purchased the Boulder facility from Amgen in September of 2015. [Read More](#)

4. [Merck KGaA Expands Biotech Production Capacity in Spain](#)

Merck KGaA has completed an expansion of its biotech plant in Tres Cantos, Madrid, Spain, resulting in a 50% increase in the facility's production capacity. Tres Cantos is the main site for the production of the active substances for Merck's Gonal-f (follitropin alfa), a drug for treating infertility, and Saizen (somatotropin (rDNA origin) for injection), a drug for treating growth hormone disorders. [Read More](#)

5. [Pfizer Launches Biosimilar to J&J's Remicade](#)

Pfizer has launched Inflectra (infliximab-dyyb) for injection, a biosimilar of Johnson & Johnson's (J&J) anti-inflammatory drug, Remicade (infliximab), and will begin shipment of Inflectra to wholesalers in the US in late November 2016. Remicade is J&J's top-selling drug with 2015 worldwide sales of \$6.56 billion. [Read More](#)

6. [FDA Issues GDUFA II Recommendations](#)

Following negotiations with the industry and other stakeholders, the FDA has issued recommendations for its performance goals and program enhancements under the Generic Drug User Fee Act (GDUFA) reauthorization for fiscal years 2018-2022, known as GDUFA II. The recommendations, which are open to further public input, are part of a process that outlines the measures that will be part of the reauthorization of GDUFA, which expires in September 2017. [Read More](#)

7. [Allergan Gets US FTC OK for \\$1.7 Billion Acquisition of Tobira...](#)

Allergan has received US antitrust clearance for its proposed \$1.7 billion acquisition of Tobira Therapeutics, a South San Francisco-based clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. The deal is expected to close by the end of the year. [Read More](#)

8. [...And Gets Antitrust OK for \\$639 Million Acquisition of Vitae Pharma](#)

Allergan has announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae Pharmaceuticals, a Fort Washington, Pennsylvania-based clinical-stage biotechnology company.

Allergan announced the acquisition of Vitae in September 2016 for approximately \$639 million.

[Read More](#)

9. [J&J Opens New Global Services Delivery Center in Tampa](#)

Johnson & Johnson has opened the new Johnson & Johnson Global Services Delivery Center in Tampa, Florida. The company plans to locate 540 people in the center by 2020, which will include functions in procurement, finance, operations, IT, and human resources. [Read More](#)

10. [EMA Issues Report on Global Initiatives for Improved Regulatory Coordination](#)

The European Medicines Agency (EMA) has published an overview of existing international regulatory initiatives for human medicines. The mapping was carried out by the EMA on behalf of the International Coalition of Medicines Regulatory Authorities to list all international projects and provides international regulatory agencies with details on the number and scope of global initiatives for coordination. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org